Efficacy of amantadine hydrochloride in patients with chronic hepatitis C

Journal of Gastroenterology

Volumn 36, Issue 11, 2001, Pages 792-793

  Nakamura, H ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; AMANTADINE; ANTIVIRUS AGENT; BIOCHEMICAL MARKER; GLYCYRRHIZIC ACID; INTERFERON; RIBAVIRIN; URSODEOXYCHOLIC ACID; VIRUS RNA; XIAO CHAI HU TANG;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL ACTIVITY; CONTROLLED STUDY; DRUG COST; DRUG EFFICACY; EDITORIAL; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOMODULATION; LIVER CARCINOGENESIS; LIVER CIRRHOSIS; PRIORITY JOURNAL; SIDE EFFECT;

AMANTADINE; ANTIVIRAL AGENTS; HEPATITIS C, CHRONIC; HUMANS;

EID: 0035214281     PISSN: 09441174     EISSN: None     Source Type: Journal    
DOI: 10.1007/s005350170025     Document Type: Editorial

References (16)

1. Combination therapy with interferon plus ribavirin for the initial treatment of chronic hepatitis C
2. Combination of ribavirin and interferon-alpha surpasses high doses of interferon-alpha alone in patients with genotype-1b-related chronic hepatitis C
3. Clinical pharmacokinetics of amantadine hydrochloride
4. Treatment of chronic hepatitis C patients with amantadine
5. Treatment of chronic hepatitis C with amantadine
6. Amantadine hydrochloride decreases serum ALT activity without effects on serum HCV-RNA in chronic hepatitis C patients
7. Amantadine for chronic hepatitis C: Pilot study in 14 patients
8. Treatment of chronic hepatitis C with amantadine
9. Amantadine monotherapy of chronic hepatitis C patients infected with genotype 1b
10. A pilot study of ribavirin and interferon beta for the treatment of chronic hepatitis C
11. Correlation of serum HCV-RNA and alanine aminotransferase levels in chronic hepatitis C patients during treatment with ribavirin
12. Effect of ribavirin on viral load and quasispecies distribution in patients infected with hepatitis C virus
13. A randomized trial of amantadine and interferon versus interferon alone as initial treatment for chronic hepatitis C
14. Interferon and ribavirin versus interferon and amantadine in interferon nonresponders with chronic hepatitis C
15. A randomized, double-blind controlled trial of interferon alpha-2b and ribavirin vs interferon alpha-2b and amantadine for treatment of chronic hepatitis C nonresponder to interferon monotherapy
16. Triple antiviral therapy as a new option for patients with interferon non-responsive chronic hepatitis C